Omeros to Present TA-TMA Treatment Advances at EBMT 2026
Event summary
- Omeros will host an industry session at the EBMT 2026 Annual Meeting on March 22, 2026, in Madrid.
- Session titled 'Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy' co-chaired by Rafael Duarte and Mohamad Mohty.
- Speakers include Miguel-Angel Perales from Memorial Sloan Kettering Cancer Center and Michelle L. Schoettler from Children’s Healthcare of Atlanta.
- Omeros' lead therapy YARTEMLEA® is FDA-approved for TA-TMA treatment in the U.S., with a marketing authorization application under review by the European Medicines Agency.
The big picture
Omeros’ presentation at EBMT 2026 underscores its focus on advancing TA-TMA treatment, a critical area in transplantation and cellular therapy. The company’s strategic partnerships and regulatory milestones highlight its position in the biotech sector, particularly in developing targeted therapies for complement-mediated diseases.
What we're watching
- Regulatory Approval
- Whether the European Medicines Agency will approve YARTEMLEA® for TA-TMA treatment, expanding its commercial reach.
- Clinical Development
- The progress of OMS1029, Omeros’ long-acting MASP-2 inhibitor, through further clinical trials.
- Strategic Partnerships
- How the asset purchase and licensing agreement with Novo Nordisk will impact Omeros' pipeline and financial strategy.
Related topics